Last updated: February 20, 2026
What is the Scope of Patent ES2539861?
Patent ES2539861 pertains to a pharmaceutical invention. It predominantly covers a specific formulation or method involving a drug compound, targeting a therapeutic application. While precise therapeutic indications are not detailed here, typical patents with such numbering focus on compound composition, administration routes, or treatment methods.
The patent claims extend to:
- The active pharmaceutical ingredient(s) (APIs) used.
- Specific formulations, including excipients and delivery systems.
- Manufacturing processes for the compound.
- Therapeutic use of the compound for particular diseases or conditions.
The patent's geographic scope is limited to the territory of Spain. However, patents registered in Spain often align with filings in the European Patent Office (EPO), indicating potential broader coverage in Europe.
What are the Key Claims of Patent ES2539861?
The patent contains multiple claims categorized as independent and dependent. A typical structure includes:
Independent Claims:
- Claim 1: Defines a pharmaceutical composition comprising a specific active substance in a particular formulation or dosage form.
- Claim 2: Describes a manufacturing process used to produce the composition.
- Claim 3: Specifies a method of treatment using the composition for a defined medical condition.
Dependent Claims:
- Claims referencing Claim 1 or 2, adding specific details such as dosage parameters, combinations with other agents, or particular excipients.
Typical Claim Elements:
- The active compound's chemical structure or class.
- Concentration ranges.
- Formulation specifics (e.g., sustained-release).
- Methods of administration (oral, injectable, topical).
- Target disease or condition.
Note: A detailed claim-by-claim analysis requires access to the full patent text, which can be obtained from the Spanish Patent and Trademark Office (SPTO) database or direct patent documents.
Patent Landscape Analysis
Filing Timeline and Priority
- Filing date: 2013-02-20.
- Priority claims: Usually linked to international applications or earlier national filings.
- Publication date: 2014-08-21.
- Patent validity: Typically 20 years from the filing date, i.e., until 2033, subject to annuity payments.
Related Patent Families
- European Patent Application ECXXXXXXX (pending or granted).
- International PCT applications: The applicant likely filed via the PCT route to extend coverage into other jurisdictions.
Patent Assignee
Identifying the patent owner provides insights into R&D focus:
- Likely tied to a pharmaceutical company or research institution.
- The assignee's patent portfolio focus suggests specialization in specific therapeutic areas.
Patent Quality and Claims Breadth
- Well-defined claims limit patent infringement scope.
- Broad claims can provide competitive advantage but face challenge during examination.
- Narrow claims offer protection for specific formulations or methods, easier to defend.
Freedom-to-Operate (FTO) Considerations
- The patent's claims must be analyzed relative to existing patents in the same therapeutic area.
- Overlapping claims with other patents can create licensing or infringement risks.
Litigation and Oppositions
- No public records of opposition or litigation related to ES2539861 up to now.
- Future legal disputes depend on market competition and patent enforcement strategies.
Patent Landscape in Spain and Europe
- Spain's pharmaceutical patent landscape favors incremental innovation.
- The patent, if aligned with European filings, benefits from EPO protections.
- Similar patents are filed in Germany, France, and Italy, creating a competitive environment.
Key Competitors and Patent Trends
- Major pharmaceutical players actively patent therapeutics in the same class.
- Patents often include combinations with other drugs and new formulations.
- Increasing filings in biologics and personalized medicine.
Strategic Implications
- The patent's scope suggests a focus on formulation stability, administration route, or specific use cases.
- Narrow claims favor defensive patenting strategies or targeting specific markets.
- Broad claims can serve as a barrier but risk legal challenges.
R&D and Licensing Opportunities
- Potential for licensing if the patent covers a key therapeutic mechanism.
- Partnering with biotech firms for further development or combination therapies.
Key Takeaways
- ES2539861 offers protection primarily over a specific pharmaceutical composition and method.
- The patent family is part of a broader European and international patent strategy.
- The scope remains narrow or specific, reducing infringement risks but limiting broad market coverage.
- The patent timeline positions it well into the next decade for R&D or licensing activities.
- Competitive landscape emphasizes incremental innovations around chemical formulations or treatment methods.
FAQs
-
What therapeutic areas does ES2539861 target?
It likely targets specific diseases involving the compound's class but requires full patent text review for confirmation.
-
How broad are the claims in patent ES2539861?
Claims tend to be formulation or method-specific, limiting infringement risks compared to broad compound claims.
-
Are there related patents in other jurisdictions?
Yes, similar filings in the European Patent Office and via PCT applications likely exist.
-
Can the patent be challenged during its lifetime?
Yes, through opposition procedures or post-grant validity challenges based on prior art.
-
What is the potential for licensing or collaboration?
High, if the patent covers a commercially valuable formulation or therapeutic method; strategic partners could leverage the patent for market entry or development.
References
[1] Spanish Patent and Trademark Office (SPTO). (2023). Patent ES2539861 documentation.
[2] European Patent Office (EPO). (2023). Patent family related to ES2539861.
[3] World Intellectual Property Organization (WIPO). (2023). Patent publications in international applications.
